Considering the wide use of SSRIs and severe clinical adverse events such as GI bleeding and intracranial bleeding, it is important for health care professionals to be informed of potential interactions with other medications known to increase bleeding risk. The objective of this narrative review is to describe the proposed mechanisms, incidence, and PK/PD interactions between SSRIs and medications that may put patients at risk for GI bleeding and intracranial bleeding if co-administered with SSRIs. The scope of this review is limited to outpatient management. synthase is required for NO production from the NO donor L-arginine. 15 Nitric oxide activates cyclic guanosine monophosphate, which acts to relax smooth vascular muscle and regulate platelet aggregation. 15 Meijer et al 16 Several SSRIs undergo biotransformation to metabolites that may also influence bleeding and platelet aggregation. Fluoxetine is converted to norfluoxetine, which has an elimination half-life of 7 to 15 days. 17 Physicians should be aware of this factor when prescribing fluoxetine because norfluoxetine is as potent as fluoxetine for inhibiting 5HT reuptake. 18 Sertraline's metabolite N-desmethylsertraline is 5 to 10 times less potent for 5HT reuptake, with lower concentrations detected in patients. [19] [20] [21] Both compounds were reported to significantly (P<.05) inhibit platelet aggregation induced by adenosine diphosphate, collagen, and thrombin. 22 Paroxetine metabolites possess very weak 5HT inhibition compared with the parent drug.
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The effects of SSRIs to inhibit platelet aggregation may be dose-dependent, as shown by in vitro studies and clinical case reports.
23,24
Increased Gastric Acid Secretion
Although not commonly recognized by physicians, SSRIs have been shown to increase gastric acid secretion directly. This action can potentially enhance the likelihood of ulcerogenic effects leading to GI bleeding. 10 The role of 5HT in gastric acid secretion was investigated by a series of animal studies. One of the studies 25 examined the use of a fluoxetine pretreatment that potentiated a metabolically stable thyrotropin analogue RX77368. Thyrotropin-releasing hormone and RX77368 act in the brain to stimulate gastric function and enhance gastric acid and pepsin secretion, motility, gastric emptying, mucosal blood flow, and, therefore, the formation of gastric erosions.
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The 5HT pathways are known to innervate a number of brain areas, including the dorsal vagal complex. 28 Vagal stimulation releases 5HT into the GI tract, where specific 5HT receptor subtypes will modulate gastric acid secretion. Gastric acid inhibition modulated by 5HT occurs with 5HT1 receptor agonists but not 5HT1A receptor agonists. 29 Other 5HT receptor agonists (eg, 5HT2, 5HT3) are not involved with gastric acid inhibition. 29 Vagal stimulation can increase the basal rate of 5HT release into the gastric lumen and portal circulation by 600% and 265%, respectively. Both fluoxetine and sertraline may have a dosedependent effect on gastric acid secretion, possibly attenuated by vagotomy. 31 Fluoxetine has also been shown to potentiate RX77368-induced gastric acid secretion, which suggests an interaction between 5HT and thyrotropin-releasing hormone to promote gastric acid REVIEW secretion. 25 The concomitant use of paroxetine and aspirin may produce a dose-dependent increase in gastric acid secretion greater than either agent alone. 32 This pharmacologic mechanism may account for the increased likelihood of upper GI bleeding when SSRIs and NSAIDs are used together.
GI Bleeding
The association between SSRIs and an increased risk of GI bleeding is well described in the literature but anticoagulants were found to increase intracranial bleeding incidence (RR, 1.73; 95% CI, 0.89-3.39), but the increase was not statistically significant. The concurrent use of antiplatelet agents, however, did not Table 2) . A large population-based cohort study reported the incidence to be 3.8 per 10,000 persons per year (0.038%). 48 One feature that may influence study results is the number of controls used per case; Renoux et al 
